

Product datasheet for TL301319

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

STYXL1 Human shRNA Plasmid Kit (Locus ID 51657)

Product data:

Product Type: shRNA Plasmids

Product Name: STYXL1 Human shRNA Plasmid Kit (Locus ID 51657)

Locus ID: 51657

Synonyms: DUSP24; MK-STYX; MKSTYX

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: STYXL1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 51657).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: <u>NM 001317785</u>, <u>NM 001317786</u>, <u>NM 001317787</u>, <u>NM 001317788</u>, <u>NM 001317789</u>,

NM 016086, NR 134486, NR 134487, NM 016086.1, NM 016086.2, BC024035, BC024035.2,

BM126964, BM824947, BM972220

UniProt ID: Q9Y6|8

Summary: Catalytically inactive phosphatase (PubMed:20180778, PubMed:23163895). By binding to


G3BP1, inhibits the formation of G3BP1-induced stress granules (PubMed:20180778,

PubMed:23163895). Does not act by protecting the dephosphorylation of G3BP1 at 'Ser-149' (PubMed:23163895). Inhibits PTPMT1 phosphatase activity (PubMed:24709986). By inhibiting PTPMT1, positively regulates intrinsic apoptosis (PubMed:21262771). May play a role in the formation of neurites during neuronal development (PubMed:29250526). [UniProtKB/Swiss-

Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).